Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the company is now trading under the new symbol "AYTU," following its corporate name change, which became effective June 8, 2015. All stock trading, filings, and market related information will be reported under this new symbol.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, Inc., stated, "When we formed what would become Aytu BioScience in April of this year, we promised to expand our portfolio of urology-focused assets. Acquiring the rights to ProstaScint® last month while continuing the development of our late-stage assets Zertane™ and RedoxSYS® marked our first major milestone for the company, and it exemplifies our core business strategy and commitment to building a portfolio of late-stage and revenue-generating products. We are pleased to be trading under the new 'AYTU' symbol, as this completes our corporate transition and allows us to move closer toward becoming a leading name in men's healthcare."
The creation of Aytu's name was inspired by Josh and Jarrett Disbrow's prior company, Arbor Pharmaceuticals, which they founded and successfully sold as a revenue-generating enterprise, and also by Ampio Pharmaceuticals, which originally developed two of Aytu's current assets Zertane and RedoxSYS. Aytu aims to build immediate value by commercializing ProstaScint and support future growth by accelerating clinical development and seeking to acquire additional complementary urological products.
AI technologies can accurately identify cases of healthcare-associated infections